Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.

Parker S, Chen NG, Foster S, Hartzler H, Hembrador E, Hruby D, Jordan R, Lanier R, Painter G, Painter W, Sagartz JE, Schriewer J, Mark Buller R.

Antiviral Res. 2012 Apr;94(1):44-53. doi: 10.1016/j.antiviral.2012.02.005. Epub 2012 Feb 18.

2.

Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

Parker S, Schriewer J, Oberle C, Robertson A, Lanier R, Painter G, Buller RM.

Antivir Ther. 2008;13(7):863-73.

3.

Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.

Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC, Lampert B, Painter G, Buller RM.

Antiviral Res. 2008 Jan;77(1):39-49. Epub 2007 Sep 4.

PMID:
17904231
4.

Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.

Parker S, Crump R, Foster S, Hartzler H, Hembrador E, Lanier ER, Painter G, Schriewer J, Trost LC, Buller RM.

Antiviral Res. 2014 Nov;111:42-52. doi: 10.1016/j.antiviral.2014.08.003. Epub 2014 Aug 13.

PMID:
25128688
5.

Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.

Parker S, Siddiqui AM, Oberle C, Hembrador E, Lanier R, Painter G, Robertson A, Buller RM.

Virology. 2009 Mar 1;385(1):11-21. doi: 10.1016/j.virol.2008.11.015. Epub 2008 Dec 18.

6.

A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.

Israely T, Paran N, Lustig S, Erez N, Politi B, Shafferman A, Melamed S.

Virol J. 2012 Jun 18;9:119. doi: 10.1186/1743-422X-9-119.

7.

A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.

Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, Parker S.

J Virol. 2010 Apr;84(8):3909-20. doi: 10.1128/JVI.02012-09. Epub 2010 Feb 3.

8.

The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4.

Robbins SJ, Jackson RJ, Fenner F, Beaton S, Medveczky J, Ramshaw IA, Ramsay AJ.

Antiviral Res. 2005 Apr;66(1):1-7. Epub 2005 Jan 25.

PMID:
15781125
9.

Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.

Rice AD, Adams MM, Wallace G, Burrage AM, Lindsey SF, Smith AJ, Swetnam D, Manning BR, Gray SA, Lampert B, Foster S, Lanier R, Robertson A, Painter G, Moyer RW.

Viruses. 2011 Jan;3(1):47-62. doi: 10.3390/v3010047. Review.

10.

Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.

Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY.

Virology. 2004 Jan 20;318(2):474-81.

11.

Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.

Rice AD, Adams MM, Lampert B, Foster S, Robertson A, Painter G, Moyer RW.

Viruses. 2011 Feb;3(2):63-82. doi: 10.3390/v3020063. Review.

12.

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER.

Antimicrob Agents Chemother. 2007 Nov;51(11):4118-24. Epub 2007 Aug 27.

13.

[THE USE OF THE MODEL MOUSE ICR--VARIOLA VIRUS FOR EVALUATION OF ANTIVIRAL DRUG EFFICACY].

Titova KA, Sergeev AA, Kabanov AS, Bulychev LE, Sergeev AA, Galakhova DO, Shishkina LN, Zamedyanskaya AS, Nesterov AE, Glotov AG, Taranov OS, Omigov VV, Agafonov AP, Sergeev AN.

Vopr Virusol. 2016;61(2):79-84. Russian.

PMID:
27451500
14.

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.

Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R.

J Virol. 2005 Oct;79(20):13139-49.

15.

Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus.

Smith SK, Self J, Weiss S, Carroll D, Braden Z, Regnery RL, Davidson W, Jordan R, Hruby DE, Damon IK.

J Virol. 2011 Sep;85(17):9176-87. doi: 10.1128/JVI.02173-10. Epub 2011 Jun 22.

16.

Ectromelia virus: the causative agent of mousepox.

Esteban DJ, Buller RM.

J Gen Virol. 2005 Oct;86(Pt 10):2645-59. Review.

PMID:
16186218
17.

Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice.

Hostetler KY, Beadle JR, Trahan J, Aldern KA, Owens G, Schriewer J, Melman L, Buller RM.

Antiviral Res. 2007 Mar;73(3):212-8. Epub 2006 Nov 9.

18.

Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.

Crump R, Korom M, Buller RM, Parker S.

Antiviral Res. 2017 Mar;139:112-116. doi: 10.1016/j.antiviral.2016.12.015. Epub 2016 Dec 27.

PMID:
28039021
19.

[Evaluation of therapeutic-prophylactic effectiveness of chemical compound NIOC-14 against ectromelia virus in vivo].

Kabanov AS, Shishkina LN, Mazurkov OIu, Skarnovich MO, Bormotov NI, Serova OA, Sergeev AA, Sergeev AA, Selivanov BA, Tikhonov AIu, Agafonov AP, Sergeev AN.

Zh Mikrobiol Epidemiol Immunobiol. 2015 Jan-Feb;(1):58-65. Russian.

PMID:
25842954
20.

Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.

Leeds JM, Fenneteau F, Gosselin NH, Mouksassi MS, Kassir N, Marier JF, Chen Y, Grosenbach D, Frimm AE, Honeychurch KM, Chinsangaram J, Tyavanagimatt SR, Hruby DE, Jordan R.

Antimicrob Agents Chemother. 2013 Mar;57(3):1136-43. doi: 10.1128/AAC.00959-12. Epub 2012 Dec 17.

Supplemental Content

Support Center